Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff
Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead cancer programs — sending it back to the preclinical drawing board — and lay off more than a quarter of its staff.
The Seattle biotech said it is discontinuing the immuno-oncology candidates after a Phase I/Ib study showed one of them, going after HER2, had little ability to kill tumors while also resulting in too many cytokine-related side effects. Because the other used the same linker technology to go after a different target, Nectin4, Silverback decided to scrap both.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
